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Introduction
In her letter, recently published in Breast Cancer Research,
María Victoria Preciado points out that some published evi-
dence suggests a possible association of breast cancer
with Epstein–Barr virus (EBV) [1]. EBV DNA has been
detected by PCR in up to 50% of cases (for a review see
[2]), and expression of the EBV-encoded nuclear antigen
EBNA1 has been demonstrated in approximately 40% of
cases by immunohistochemistry using the mAb designated
2B4 [3]. In combination, these findings seem to implicate
EBV in the pathogenesis of breast carcinoma. Interestingly,
however, most investigators agree that the EBV-encoded
RNAs (EBERs), a hallmark of latent EBV infection, are not
detectable in breast carcinoma tumour cells [2].
In two independent studies, we have analysed breast carci-
nomas for evidence of EBV infection [4,5]. In whole tissue
sections, EBV DNA was detectable by quantitative PCR in
up to 21% of cases at low copy number [5]. However, this
does not allow conclusions regarding the cellular source of
the viral DNA. We therefore attempted to detect viral DNA
directly in the neoplastic cells using a sensitive DNA in situ
hybridisation assay [4] or using quantitative PCR of
microdissected tumour cells [5]. These studies yielded
negative results [4,5]. In support of these results, in situ
hybridisation for the detection of the EBERs was also neg-
ative in all cases while occasional EBV-positive non-neo-
plastic lymphocytes were detected by this approach [4].
The latter finding explains the detection of EBV DNA in
whole tumour sections by PCR.
There remains the issue of reactivity of breast carcinoma
cells with the EBNA1-specific mAb 2B4. We have previ-
ously reported that this mAb yields nuclear labelling not only
of EBV-infected cells, but also of some EBV-negative cells,
notably epithelial cells [6]. We therefore recommended the
use of another EBNA1-specific mAb, 1H4, when studying
epithelial tumours [6]. In one of our recent studies, 31% of
breast cancers, including cases that had tested negative for
EBV genomes by PCR of microdissected tumour cells,
showed nuclear labelling of tumour cells with the 2B4 mAb
[5]. However, no labelling of tumour cells was observed
with both mAbs in the other study [4]. The discrepancy
between these results may relate to technical differences
(e.g. fixation of tissues or antigen retrieval).
We thus conclude that EBV is not present in tumour cells
of breast carcinomas. The reactivity of tumour cell nuclei
with the EBNA1-specific mAb 2B4 is likely to be the result
of cross-reactivity with an unrelated epitope. There is
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